Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Solventum trades at a significant discount to medical technology peers, with a forward P/E of ~13x and suppressed EV/EBITDA multiples. Management is executing a portfolio optimization, including a potential spin-off of the Health Information Systems segment to unlock value and reduce debt. Raised 2026 EPS guidance to $7.10-$7.20 and operating margins to 22.2%-22.7%, signaling margin expansion and improved free cash flow allocation.
| Software Industry | Information Technology Sector | Bryan C. Hanson CEO | XMEX Exchange | US83444M1018 ISIN |
| US Country | 20,584 Employees | - Last Dividend | - Last Split | - IPO Date |
Solventum Corporation is a cutting-edge healthcare company established in 2023 and headquartered in Saint Paul, Minnesota. Specializing in the development, manufacture, and commercialization of diverse solutions aimed at addressing urgent customer and patient needs, the company operates across four main segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Solventum Corporation stands out in the healthcare industry by offering a wide-ranging portfolio of innovative products and services, demonstrating its commitment to improving healthcare outcomes and enhancing the efficiency of medical and dental professions.